Claims for Patent: 11,020,448

Summary for Patent: 11,020,448

Title:	Methods comprising desmopressin
Abstract:	The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
Inventor(s):	Klein; Bjarke Mirner (Frederiksberg, DK), Norgaard; Jens Peter (Frederiksberg, DK)
Assignee:	FERRING B.V. (Hoofddorp, NL)
Application Number:	16/162,453
Patent Claims:	1. A method of further reducing nocturnal voids in a female patient in need thereof, comprising: measuring the patient's serum sodium level; administering to the patient, with a serum sodium level of at least 130 mmol/L, prior to bedtime, an orodispersible dose of desmopressin chosen from 25 .mu.g, 50 .mu.g, and 100 .mu.g, over a first treatment period of about 28 days, wherein the dose is taken from 0.8 to 3 hours prior to the patient's bedtime and once daily and the dose is measured as the free base; measuring the patient's serum sodium level after the first treatment period; and continuing to administer the orodispersible dose of desmopressin prior to bedtime over a second contiguous treatment period of at least 28 days to about 1 year if the female patient has a serum sodium level of at least 130 mmol/L, wherein the nocturnal voids over the second treatment period are further reduced in view of the reduction in the nocturnal voids over the first treatment period and wherein the reduction in the nocturnal voids over the first treatment period is determined based on compared to the patient's nocturnal voids before administration of the orodispersible dose of desmopressin for the first treatment period. 2. The method according to claim 1, wherein the dose of desmopressin is supplied in the form of the acetate salt of desmopressin. 3. The method according to claim 1, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid. 4. The method according to claim 1, wherein the patient in need thereof has nocturia or nocturnal polyuria. 5. The method according to claim 1, wherein the reduction in nocturnal voids ranges from about one nocturnal void to about two nocturnal voids compared to the patient's nocturnal voids before administration of the dose. 6. The method according to claim 1, wherein the second contiguous treatment period ranges from about 8 weeks to about 1 year. 7. The method according to claim 1, wherein the second contiguous treatment period is selected from about 8 weeks, about 12 weeks, about 20 weeks, about 28 weeks, and about 52 weeks. 8. The method according to claim 7, wherein the second contiguous treatment period is about 8 weeks. 9. The method according to claim 7, wherein the second contiguous treatment period is about 20 weeks. 10. The method according to claim 7, wherein the second contiguous treatment period is about 52 weeks. 11. The method according to claim 7, wherein the second contiguous treatment period is about 1 year. 12. The method according to claim 1, wherein the dose is taken without water. 13. The method according to claim 1, wherein the dose is taken approximately 1 hour prior to the patient's bedtime.